Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Myeloproliferative Disorders Treatment Market size was over USD 9.66 billion in 2024 and is poised to exceed USD 14.92 billion by 2037, growing at over 3.4% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of myeloproliferative disorders treatment is evaluated at USD 9.94 billion.
The increasing investments in research and development activities along with rising incidences of myeloproliferative disorders is predicted to boost the market growth. Furthermore, the rising awareness for molecular abnormalities and cellular pathways associated with the MPN pathogenesis is expected to facilitate the development of clinical trials and novel drugs, which is estimated to boost the market growth. There is no known cure for this disorder, so the treatment is focused on treating the symptoms, which include weight loss, pale skin, blood clotting and excessive blood loss, splenomegaly, cachexia, and others. This raises the scope for R&D activities for developing novel drugs and treatment methods for this disorder, which is estimated to boost the market growth.
-Treatment-Market-Size.jpg)
Myeloproliferative Disorders Treatment Sector: Growth Drivers and Challenges
Growth Drivers
- Rising Number of Deaths and Increased about Myeloproliferative Disorder
- Collaboration Between Pharma Companies
Restraints
- Side Effects Associated with Myeloproliferative Disorder Treatments
Myeloproliferative Disorders Treatment Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
3.4% |
|
Base Year Market Size (2024) |
USD 9.66 billion |
|
Forecast Year Market Size (2037) |
USD 14.92 billion |
|
Regional Scope |
|
Myeloproliferative Disorders Treatment Segmentation
The market is segmented by type, treatment, and by end-user. Based on end-user, the market is segmented into hospitals, home care, specialty clinics, and others out of which hospital segment is anticipated to hold the largest market share throughout the forecast period. This can be attributed to growing healthcare facilities and a rising number of hospitals along with the increasing incidences of myeloproliferative disorders globally. Similarly, the segment for specialty clinics is also expected to grow at a significant rate over the forecast period as a result of the increasing number of specialized and disease-specific clinics which is estimated to boost the segment growth.
Our in-depth analysis of the global market includes the following segments:
|
By Type |
|
|
By Treatment |
|
|
By End-User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportMyeloproliferative Disorders Treatment Industry - Regional Synopsis
North America industry is predicted to hold largest revenue share by 2037, owing to undergoing advanced research and development in the healthcare sector, along with presence of leading pharmaceutical companies conducting innovative clinical experiments. The market in the North America region is estimated to hold the largest market share in the market over the forecast period owing to the undergoing advanced research and development in the healthcare sector along with the presence of leading pharmaceutical companies conducting innovative clinical experiments. The market in the Europe region is projected to garner significant revenue during the forecast period owing to the development of novel treatment options, high demand for targeted therapies, and increasing geriatric population in the region.
Companies Dominating the Myeloproliferative Disorders Treatment Landscape
- Incyte Corporation,
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Bristol-Myers Squibb Company,
- Novartis AG, Pfizer Inc.,
- Teva Pharmaceutical Industries Ltd.,
- Takeda Pharmaceutical Company Limited
There is no known cure for the myeloproliferative disorder, however, there are various drugs and treatments to improve the symptoms and prolong the patient’s life. Major companies, developing these drugs, include,
In the News
Author Credits: Radhika Pawar
- Report ID: 3034
- Published Date: Dec 24, 2024
- Report Format: PDF, PPT
